Silac Versus Phenol for the Treatment of Pilonidal Sinus Disease: A Randomized Controlled Trial

Condition(s) studied

Investigational drug(s) / intervention(s)

SiLac (Laser Ablation): Laser ablation of the pilonidal sinus tract performed according to the study protocol.

Phenol Application: Chemical ablation with phenol performed according to the study protocol.

Study summary

Pilonidal sinus disease is a common condition affecting young adults and is associated with pain, infection, and reduced quality of life. Various minimally invasive treatment options have been developed to reduce recurrence and improve recovery time. Among these methods, Silac (laser ablation) and phenol application are frequently used techniques.

The aim of this prospective randomized controlled trial is to compare the effectiveness and safety of Silac and phenol treatments in patients with primary pilonidal sinus disease. Eligible patients will be randomly assigned to receive either Silac or phenol treatment. The primary outcome of the study is recurrence rate. Secondary outcomes include postoperative pain, healing time, time to return to work, patient satisfaction, and treatment cost.

Patient recruitment is planned over a 6-month period, and each participant will be followed for 6 months after treatment. The total study duration will be 12 months. The results of this study are expected to provide evidence to guide the selection of minimally invasive treatment options for primary pilonidal sinus disease.

Eligibility

Primary outcome measure(s)

• Recurrence Rate — 6 month
  Recurrence of pilonidal sinus disease defined as the presence of a new sinus opening, discharge, abscess formation, or need for additional surgical intervention during follow-up.

Trial sites (1)

More Izmir City Hospital trials in Turkey

Other trials for the same condition